Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11810185 | 0.87 | GPR35 (0.76) | GPR35ALDH1A1GAAL3MBTL1NPC1 | |
| SCHEMBL11571030 | 0.85 | GPR35 (0.74) | GPR35ALDH1A1GAAL3MBTL1KMT2A | |
| SCHEMBL11802630 | 0.84 | GPR35 (0.73) | GPR35ALDH1A1GAAL3MBTL1 | |
| SCHEMBL11399533 | 0.81 | GPR35 (0.68) | GPR35ALDH1A1GAAL3MBTL1KMT2A | |
| SCHEMBL11390592 | 0.81 | GPR35 (0.68) | GPR35ALDH1A1GAAL3MBTL1NPC1 | |
| SCHEMBL11802638 | 0.81 | GPR35 (0.67) | GPR35ALDH1A1GAAL3MBTL1PTPN1 | |
| SCHEMBL11617934 | 0.81 | GPR35 (0.67) | GPR35ALDH1A1GAAL3MBTL1KMT2A | |
| SCHEMBL11806509 | 0.80 | GPR35 (0.67) | GPR35ALDH1A1GAAL3MBTL1KMT2A | |
| SCHEMBL11619425 | 0.80 | GPR35 (0.66) | GPR35ALDH1A1GAAL3MBTL1KMT2A | |
| SCHEMBL11393671 | 0.79 | GPR35 (0.73) | GPR35ALDH1A1GAAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113754562-B | Method for synthesizing lodoxamide or diethyl ester thereof | 中国科学院上海营养与健康研究所 | 2023-07-25 | — | — | CN | claimed |
| US-4501754-A | ADMINISTERING DISODIUMCHROMOGLYCATE AND ANTIALLERGENIC BIOLOGUES | THE UPJOHN COMPANY (US) | 1985-02-26 | — | — | US | claimed |
| US-4447449-A | ADMINISTERING AN ANTIALLERGENIC AGENT | THE UPJOHN COMPANY (US) | 1984-05-08 | — | — | US | claimed |
| US-3993679-A | ANTIALLERGY | THE UPJOHN COMPANY (US) | 1976-11-23 | — | — | US | claimed |
| CN-113754562-B | Method for synthesizing lodoxamide or diethyl ester thereof | 中国科学院上海营养与健康研究所 | 2023-07-25 | — | — | CN | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| WO-2016118787-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| US-4281151-A | ANTIALLERGENS, ANTIANAPHYLACTIC AGENTS | THE UPJOHN COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4186127-A | ANTIALLERGENS | THE UPJOHN COMPANY (US) | 1980-01-29 | — | — | US | disclosed |
| US-4159278-A | PROPHYAXIS, ANTIALLERGENS, SENSITIZATION | THE UPJOHN COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4095028-A | PROPHYLAXIS, ALLERGIES | THE UPJOHN COMPANY (US) | 1978-06-13 | — | — | US | disclosed |
| US-4089973-A | Cyano phenylene dioxamic acid compounds used in the treatment of allergy | THE UPJOHN COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
| US-4011337-A | ANTIALLERGENS | THE UPJOHN COMPANY (US) | 1977-03-08 | — | — | US | disclosed |
| US-3993679-A | ANTIALLERGY | THE UPJOHN COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
| US-3962308-A | Process for converting esters to amine salts | THE UPJOHN COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216314-A1 | TOPICAL FORMULATIONS | SMURF1, SGMS1, SPTLC1 | GPR35 783/4885ALDH1A1 3342/4885GAA 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.